Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (Leukemia, (2019), 33, 8, (1910-1922), 10.1038/s41375-019-0413-0)

H. Pfeifer*, G. Cazzaniga, V. H.J. van der Velden, J. M. Cayuela, B. Schäfer, O. Spinelli, S. Akiki, S. Avigad, I. Bendit, K. Borg, H. Cavé, L. Elia, S. C. Reshmi, G. Gerrard, S. Hayette, M. Hermanson, A. Juh, T. Jurcek, M. C. Chillón, C. HomburgG. Martinelli, V. Kairisto, T. Lange, T. Lion, M. C. Mueller, F. Pane, L. Rai, C. Damm-Welk, T. Sacha, S. Schnittger, T. Touloumenidou, H. Valerhaugen, P. Vandenberghe, J. Zuna, H. Serve, E. Herrmann, S. Markovic, J. J.M. van Dongen, O. G. Ottmann

*Corresponding author for this work

Research output: Contribution to journalComment/debate

1 Scopus citations

Fingerprint

Dive into the research topics of 'Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (Leukemia, (2019), 33, 8, (1910-1922), 10.1038/s41375-019-0413-0)'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry